Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has demonstrated insulin dependent and independent cardio-protective actions in DCM by increasing glucagon-like peptide-1 (GLP-1), and following activation of, at least, its pancreatic and cardiac receptors (GLP-1R) [8, 9]. The gene discussed is GLP1R; the disease is familial dilated cardiomyopathy.